We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Rapid Test That Identifies Deteriorating COVID-19 Patients with Greater Accuracy than Existing Tests Presented at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

A groundbreaking study on a new rapid test that identifies COVID-19 patients who will deteriorate with greater accuracy than existing tests was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

A team of researchers from MeMed (Haifa, Israel) has developed the test that predicts COVID-19 outcomes with high accuracy. In 15 minutes, the test measures blood levels of TRAIL and IP-10, two proteins that the immune system produces in response to viral infections, and CRP, a general marker of infection severity. The test then uses these values to calculate a COVID-19 Severity score on a scale of 0-100, with 100 indicating the highest likelihood of severe outcome.

To develop this test, the researchers first used a rapid point-of-care instrument that MeMed previously built to measure TRAIL, IP-10, and CRP in a group of 518 COVID-19 patients, 113 of whom had a severe outcome. The researchers analyzed the data from this group with a machine learning algorithm in order to create the model that serves as the basis for the COVID-19 Severity score. Through statistical analysis, the researchers then determined that the COVID-19 Severity score has an area under the curve (AUC) of 0.86. This means that it outperforms other COVID-19 severity stratification tests in terms of accuracy, including the commonly used biomarker IL-6, which only has an AUC of 0.77.

“There are three elements that are novel about this test,” said Eran Eden, PhD, Co-founder & CEO of MeMed. “First, we’re using the body’s immune response to tell us what’s going on with the patient. Second, instead of using just one biomarker, we’re combining three complementary markers to get a more holistic picture. And third, we’re using a novel platform that is able to measure these specific proteins from blood within 15 minutes, making this test clinically applicable to the workflow in today’s emergency departments.”

Related Links:
MeMed

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Tick Borne Diseases Test
Savvygen Tick Borne

Print article
AACC

Channels

Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Molecular Diagnostics

view channel
Image: The PrismRA blood test helps target best treatments for patients with rheumatoid arthritis (Photo courtesy of Scipher Medicine)

Groundbreaking Rheumatoid Arthritis Blood Test Predicts Treatment Response

Rheumatoid arthritis (RA), an autoimmune disease affecting joints and other systems in the body, impacts millions globally. Typically, the initial biologic treatment involves anti-inflammatory drugs from... Read more

Hematology

view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more

Immunology

view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more

Microbiology

view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more

Pathology

view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more

Industry

view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.